NEW YORK and MELBOURNE, Australia, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; Nasdaq: MESO)
today announced that Tasly Pharmaceutical Group has received People's Republic of China governmental approvals of Overseas Direct
Investment from Tianjin Commission of Commerce and Tianjin Development and Reform Commission to enter into an investment agreement
as well as a development and collaboration agreement with Mesoblast to commercialize cell therapies for cardiovascular diseases in
China.
Under the terms of the agreements with Tasly, on closing Mesoblast will receive US$40 million, comprising a US$20 million
upfront technology access fee and US$20 million for equity in Mesoblast purchased by Tasly at AUD$1.86 per share. The transaction
is subject to filing with the State Administration of Foreign Exchange.
About Tasly Pharmaceutical Group
Tasly Pharmaceutical Group (SHA: 600535) is one of the largest pharmaceutical companies in China with more than 20
years of operational history. Its business focuses on R&D, manufacturing and commercialization of innovative modern traditional
Chinese medicine, biologics and chemical drugs in the therapeutic areas of cardiology, metabolism and oncology. Tasly has the only
marketed biological product for cardiovascular diseases approved in China. It has one of the largest pharmaceutical sales and
marketing teams, including 809 offices established in 29 regions covering all the main therapeutic areas, and a vast distribution
network across approximately 20,000 hospitals in China. At 2017, its total annual revenues exceeded US$2.5 billion.
About Mesoblast
Mesoblast Limited (ASX: MSB; Nasdaq: MESO) is a world leader in developing allogeneic (off-the-shelf) cellular medicines. The
Company has leveraged its proprietary technology platform to establish a broad portfolio of late-stage product candidates with
three product candidates in Phase 3 trials – acute graft versus host disease, chronic heart failure and chronic low back pain due
to degenerative disc disease. Through a proprietary process, Mesoblast selects rare mesenchymal lineage precursor and stem cells
from the bone marrow of healthy adults and creates master cell banks, which can be industrially expanded to produce thousands of
doses from each donor that meet stringent release criteria, have lot to lot consistency, and can be used off-the-shelf without the
need for tissue matching. Mesoblast has facilities in Melbourne, New York, Singapore and Texas and is listed on the Australian
Securities Exchange (MSB) and on the Nasdaq (MESO). www.mesoblast.com
Forward-Looking Statements
This announcement includes forward-looking statements that relate to future events or our future financial performance
and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity,
performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed
or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995 and other applicable federal securities laws. Forward- looking statements
include, but are not limited to, statements about: the potential benefits of this alliance and the parties’ ability to maintain the
alliance; whether the conditions to the transaction will be satisfied in a timely manner, if at all; the parties’ ability to
advance product candidates into, enroll and successfully complete, clinical studies, advance their manufacturing capabilities, and
obtain regulatory filings and approvals. There are many uncertainties and risks that may cause our actual results, performance or
achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you
should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or
revise any forward-looking statements, whether as a result of new information, future developments or otherwise.
For further information, please contact:
